| Cash Flow | 2025-09-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Net income | 348,536 | 1,021,018 | 655,977 | 311,355 |
| Depreciation and amortization | 47,698 | 134,845 | 91,169 | 44,730 |
| Amortization of right-of-use assets | 9,971 | 26,678 | 18,443 | 8,980 |
| Stock-based compensation costs | 21,160 | 66,910 | 42,790 | 20,156 |
| (gain) loss attributable to equity method investments (note 5) | 1,489 | 2,375 | 2,040 | 963 |
| (gain) loss on equity investments (note 5) | -6,190 | -7,765 | -2,119 | -680 |
| Non-cash restructuring expenses (note 11) | - | 0 | 0 | - |
| Accounts receivable | -29,970 | 71,469 | 31,436 | -36,417 |
| Inventories | 14,663 | 48,032 | 77,895 | 70,254 |
| Prepaid expenses, net deferred income taxes and other current assets | -2,312 | -35,612 | 43,746 | 123 |
| Accounts payable, accrued expenses, income taxes payable and other | 7,636 | 41,870 | -21,220 | -25,440 |
| Net cash provided by (used in) operating activities | 457,321 | 1,212,822 | 634,161 | 325,538 |
| Purchases of property, plant and equipment | 42,965 | 59,280 | 38,484 | 17,840 |
| Patent registration and acquisition costs | 2,814 | 7,584 | 4,592 | 1,767 |
| Business acquisitions, net of cash acquired | 522 | 670 | 670 | 0 |
| Purchases of investments (note 5) | 2,173 | 4,403 | 2,350 | 1,350 |
| Proceeds from exits of investments (note 5) | 0 | 4,378 | 4,378 | 4,128 |
| Proceeds (payments) on maturity of foreign currency contracts | 4,104 | -1,227 | -7,172 | -18,975 |
| Net cash provided by (used in) investing activities | -52,578 | -66,332 | -34,546 | 2,146 |
| Proceeds from issuance of common stock, net | 8,205 | 44,283 | 35,260 | 8,383 |
| Taxes paid related to net share settlement of equity awards | 719 | 17,487 | 17,123 | 389 |
| Purchases of treasury stock | 150,010 | 200,017 | 124,991 | 50,005 |
| Payments of business combination contingent consideration | 0 | 855 | 855 | 855 |
| Proceeds from borrowings, net of borrowing costs | - | 0 | 0 | 0 |
| Repayment of borrowings | 0 | 35,000 | 35,000 | 30,000 |
| Dividends paid | 87,750 | 233,290 | 155,586 | 77,891 |
| Net cash provided by (used in) financing activities | -230,274 | -442,366 | -298,295 | -150,757 |
| Effect of exchange rate changes on cash | -71 | -9,774 | -17,737 | 11,073 |
| Net increase (decrease) in cash and cash equivalents | 174,398 | 694,350 | 283,583 | 188,000 |
| Cash and cash equivalents at beginning of period | 1,209,450 | 238,361 | 238,361 | 238,361 |
| Cash and cash equivalents at end of period | 1,383,848 | 932,711 | 521,944 | 426,361 |
RESMED INC (RSMDF)
RESMED INC (RSMDF)